R-E Yoo1, S H Choi2, T M Kim3, S-H Lee4, C-K Park5, S-H Park6, I H Kim7, T J Yun4, J-H Kim4, C H Sohn8. 1. From the Departments of Radiology (R.-E.Y., S.H.C., T.J.Y., J.-H.K, C.H.S) Center for Nanoparticle Research (R.-E.Y., S.H.C.) Institute for Basic Science and School of Chemical and Biological Engineering (R.-E.Y., S.H.C.), Seoul National University, Seoul, Korea. 2. From the Departments of Radiology (R.-E.Y., S.H.C., T.J.Y., J.-H.K, C.H.S) Center for Nanoparticle Research (R.-E.Y., S.H.C.) Institute for Basic Science and School of Chemical and Biological Engineering (R.-E.Y., S.H.C.), Seoul National University, Seoul, Korea. verocay@snuh.org. 3. Departments of Internal Medicine (S.-H.L., T.M.K.). 4. From the Departments of Radiology (R.-E.Y., S.H.C., T.J.Y., J.-H.K, C.H.S). 5. Department of Neurosurgery (C.-K.P.), Biomedical Research Institute; Seoul National University College of Medicine, Seoul, Korea. 6. Pathology (S.-H.P.) Departments of Internal Medicine (S.-H.L., T.M.K.). 7. Radiation Oncology (C.H.S., I.H.K.), Cancer Research Institute. 8. From the Departments of Radiology (R.-E.Y., S.H.C., T.J.Y., J.-H.K, C.H.S) Radiation Oncology (C.H.S., I.H.K.), Cancer Research Institute.
Abstract
BACKGROUND AND PURPOSE: Subependymal enhancement and DWI have been reported to be useful MR imaging markers for identifying true progression. Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide. MATERIALS AND METHODS: Forty-two patients with glioblastoma multiforme with newly developed or enlarged enhancing lesions on the first follow-up MR images obtained within 2 months of concurrent chemoradiotherapy completion were included. Subependymal enhancement was analyzed for the presence, location, and pattern (local or distant relative to enhancing lesions). The mean ADC value and the fifth percentile of the cumulative ADC histogram were determined. A multiple logistic regression analysis was performed to identify independent factors associated with true progression. RESULTS: Distant subependymal enhancement (ie, extending >1 cm or isolated from the enhancing lesion) was significantly more common in true progression (n = 24) than in pseudoprogression (n = 18) (P = .042). The fifth percentile of the cumulative ADC histogram was significantly lower in true progression than in pseudoprogression (P = .014). Both the distant subependymal enhancement and the fifth percentile of the cumulative ADC histogram were independent factors associated with true progression (P = .041 and P = .033, respectively). Sensitivity and specificity for the diagnosis of true progression were 83% and 67%, respectively, by using both factors. CONCLUSIONS: Both the distant subependymal enhancement and the fifth percentile of the cumulative ADC histogram were significant independent factors predictive of true progression.
BACKGROUND AND PURPOSE:Subependymal enhancement and DWI have been reported to be useful MR imaging markers for identifying true progression. Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide. MATERIALS AND METHODS: Forty-two patients with glioblastoma multiforme with newly developed or enlarged enhancing lesions on the first follow-up MR images obtained within 2 months of concurrent chemoradiotherapy completion were included. Subependymal enhancement was analyzed for the presence, location, and pattern (local or distant relative to enhancing lesions). The mean ADC value and the fifth percentile of the cumulative ADC histogram were determined. A multiple logistic regression analysis was performed to identify independent factors associated with true progression. RESULTS: Distant subependymal enhancement (ie, extending >1 cm or isolated from the enhancing lesion) was significantly more common in true progression (n = 24) than in pseudoprogression (n = 18) (P = .042). The fifth percentile of the cumulative ADC histogram was significantly lower in true progression than in pseudoprogression (P = .014). Both the distant subependymal enhancement and the fifth percentile of the cumulative ADC histogram were independent factors associated with true progression (P = .041 and P = .033, respectively). Sensitivity and specificity for the diagnosis of true progression were 83% and 67%, respectively, by using both factors. CONCLUSIONS: Both the distant subependymal enhancement and the fifth percentile of the cumulative ADC histogram were significant independent factors predictive of true progression.
Authors: N G Burnet; R Jena; K E Burton; G S J Tudor; J E Scaife; F Harris; S J Jefferies Journal: Clin Oncol (R Coll Radiol) Date: 2014-05-17 Impact factor: 4.126
Authors: Eiji Matsusue; James R Fink; Jason K Rockhill; Toshihide Ogawa; Kenneth R Maravilla Journal: Neuroradiology Date: 2009-10-16 Impact factor: 2.804
Authors: P K Sneed; P H Gutin; D A Larson; M K Malec; T L Phillips; M D Prados; C O Scharfen; K A Weaver; W M Wara Journal: Int J Radiat Oncol Biol Phys Date: 1994-07-01 Impact factor: 7.038
Authors: Christina M Flies; Karlijn H van Leuken; Marlies Ten Voorde; Joost J C Verhoeff; Filip Y F De Vos; Tatjana Seute; Pierre A Robe; Theodoor D Witkamp; Jeroen Hendrikse; Jan Willem Dankbaar; Tom J Snijders Journal: Neurology Date: 2022-04-18 Impact factor: 11.800